Agios Pharmaceuticals, Inc. (0HB0.L)
USD 31.71
(-6.43%)
USD 31.71
(-6.43%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 408.8 Million USD | -70.28% |
| 2022 | 383.02 Million USD | 6.5% |
| 2021 | 359.64 Million USD | 13.4% |
| 2020 | 317.14 Million USD | -39.74% |
| 2019 | 526.3 Million USD | 17.4% |
| 2018 | 448.29 Million USD | 25.44% |
| 2017 | 357.37 Million USD | 34.77% |
| 2016 | 265.16 Million USD | 51.98% |
| 2015 | 174.47 Million USD | 812.54% |
| 2014 | 19.12 Million USD | 92.57% |
| 2013 | 9.92 Million USD | 40.56% |
| 2012 | 7.06 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 33.95 Million USD | -65.45% |
| 2024 Q3 | 110.99 Million USD | 222.9% |
| 2024 Q1 | 98.28 Million USD | -11.76% |
| 2023 Q1 | 91.27 Million USD | -7.52% |
| 2023 Q4 | 111.39 Million USD | 5.05% |
| 2023 FY | 408.8 Million USD | 6.73% |
| 2023 Q3 | 106.04 Million USD | 11.81% |
| 2023 Q2 | 94.84 Million USD | 3.91% |
| 2022 Q3 | 89.59 Million USD | -8.59% |
| 2022 FY | 383.02 Million USD | 6.5% |
| 2022 Q4 | 98.69 Million USD | 10.15% |
| 2022 Q2 | 98.01 Million USD | 1.33% |
| 2022 Q1 | 96.72 Million USD | -3.49% |
| 2021 Q1 | 86.32 Million USD | -65.01% |
| 2021 Q2 | 86.52 Million USD | 0.24% |
| 2021 Q3 | 86.57 Million USD | 0.05% |
| 2021 Q4 | 100.21 Million USD | 15.76% |
| 2021 FY | 359.64 Million USD | 13.4% |
| 2020 Q4 | 246.72 Million USD | 770.36% |
| 2020 Q1 | 31.67 Million USD | -9.08% |
| 2020 Q2 | 29.17 Million USD | -7.87% |
| 2020 FY | 317.14 Million USD | -39.74% |
| 2020 Q3 | 28.34 Million USD | -2.85% |
| 2019 FY | 526.3 Million USD | 17.4% |
| 2019 Q4 | 34.83 Million USD | 5.5% |
| 2019 Q2 | 32.38 Million USD | 1.88% |
| 2019 Q3 | 33.01 Million USD | 1.94% |
| 2019 Q1 | 31.79 Million USD | -0.21% |
| 2018 Q2 | 26.63 Million USD | 8.48% |
| 2018 FY | 448.29 Million USD | 25.44% |
| 2018 Q4 | 31.85 Million USD | 2.42% |
| 2018 Q3 | 31.1 Million USD | 16.79% |
| 2018 Q1 | 24.54 Million USD | 8.09% |
| 2017 Q3 | 17.45 Million USD | 8.23% |
| 2017 Q4 | 22.71 Million USD | 30.1% |
| 2017 FY | 357.37 Million USD | 34.77% |
| 2017 Q1 | 14.82 Million USD | -3.62% |
| 2017 Q2 | 16.12 Million USD | 8.82% |
| 2016 Q1 | 10.83 Million USD | 6.42% |
| 2016 Q2 | 12.64 Million USD | 16.67% |
| 2016 Q3 | 11.85 Million USD | -6.25% |
| 2016 FY | 265.16 Million USD | 51.98% |
| 2016 Q4 | 15.37 Million USD | 29.74% |
| 2015 FY | 174.47 Million USD | 812.54% |
| 2015 Q3 | 9.92 Million USD | 11.18% |
| 2015 Q2 | 8.92 Million USD | 28.4% |
| 2015 Q1 | 6.95 Million USD | 6.97% |
| 2015 Q4 | 10.18 Million USD | 2.58% |
| 2014 Q3 | 5.16 Million USD | 24.03% |
| 2014 FY | 19.12 Million USD | 92.57% |
| 2014 Q4 | 6.5 Million USD | 25.84% |
| 2014 Q1 | 3.28 Million USD | -11.3% |
| 2014 Q2 | 4.16 Million USD | 26.67% |
| 2013 Q4 | 3.7 Million USD | 46.29% |
| 2013 Q1 | 1.85 Million USD | 19.18% |
| 2013 Q2 | 1.83 Million USD | -0.86% |
| 2013 Q3 | 2.53 Million USD | 38.02% |
| 2013 FY | 9.92 Million USD | 40.56% |
| 2012 FY | 7.06 Million USD | 0.0% |
| 2012 Q4 | 1.55 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 76.59% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -3267.153% |
| Myriad Genetics, Inc. | 600.1 Million USD | 31.877% |
| Evolus, Inc. | 189.75 Million USD | -115.434% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 47.561% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 80.671% |
| uniQure N.V. | 285.08 Million USD | -43.397% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -633.205% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -48.283% |
| bluebird bio, Inc. | 240.23 Million USD | -70.171% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -742.864% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 77.289% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -10.904% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 4.407% |
| Dynavax Technologies Corporation | 219.14 Million USD | -86.546% |
| Editas Medicine, Inc. | 247.3 Million USD | -65.305% |
| FibroGen, Inc. | 398.11 Million USD | -2.686% |
| Geron Corporation | 70.44 Million USD | -480.352% |
| Blueprint Medicines Corporation | 722.86 Million USD | 43.446% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 80.087% |
| Illumina, Inc. | 3.81 Billion USD | 89.279% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 9.354% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -944.124% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 74.394% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -186.956% |
| Adicet Bio, Inc. | 152.03 Million USD | -168.884% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 69.959% |
| Insmed Incorporated | 949.26 Million USD | 56.934% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 25.883% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 62.474% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -815.23% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 22.723% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 98.993% |
| Waters Corporation | 943.51 Million USD | 56.672% |
| Zoetis Inc. | 2.76 Billion USD | 85.215% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 96.013% |
| Biogen Inc. | 5.2 Billion USD | 92.146% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -78.768% |
| Nektar Therapeutics | 190.9 Million USD | -114.143% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -305.453% |
| Perrigo Company plc | 1.52 Billion USD | 73.254% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 14.181% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -238.817% |
| Verastem, Inc. | 92.08 Million USD | -343.949% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 91.439% |
| Imunon, Inc. | 21.03 Million USD | -1843.878% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -2839.012% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -50.353% |
| Homology Medicines, Inc. | 9.87 Million USD | -4039.808% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 85.479% |
| OPKO Health, Inc. | 574.68 Million USD | 28.864% |
| Exelixis, Inc. | 1.58 Billion USD | 74.237% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -36.579% |
| TG Therapeutics, Inc. | 198.47 Million USD | -105.974% |
| Incyte Corporation | 1.19 Billion USD | 65.661% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 60.842% |